Organization | Validus Pharmaceuticals

Validus Pharmaceuticals Report issue

Contributed to NME For profit Phase 4

Founded: Parsippany NJ United States (2007)

Status: No NME R&D (2007)

Organization Overview

First Clinical Trial

2007

NCT00150553

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

US PHARM HOLDINGS | US PHARMS HOLDINGS I | VALIDUS PHARMS | VALIDUS PHARMS INC

Active Ingredients

Marketed Drugs (16)

benazepril (lotensin) (1991)

bromocriptine (parlodel) (1978 NDA)

bumetanide (bumex) (1983)

calcitriol (rocaltrol) (1978 NDA)

carbamazepine (tegretol) (2004)

cefotaxime (claforan) (1981 NDA)

desipramine (pertofrane) (1964)

dolasetron (anzemet) (1997 NDA)

ergocalciferol (drisdol) (1941)

furosemide (lasix) (1966)

hexamethylenetetramine (1976)

hydrochlorothiazide (esidrix) (1984)

isocarboxazid (marplan) (1959 NDA)

meperidine (demerol) (1942)

metoprolol (lopressor) (1978)

pentoxifylline (trental) (1984 NDA)

Drugs in Phase 4 Trials (1)

carbamazepine (tegretol) (4 trials)

Indications

Approved Indications

Bone Diseases, Infectious

Central Nervous System Infections

Diabetes Mellitus, Type 2

Genital Diseases, Female

Hyperprolactinemia

Hypoparathyroidism

Infertility, Female

Intermittent Claudication

Intraabdominal Infections

Kidney Failure, Chronic

Parkinson Disease

Postoperative Nausea and Vomiting

Respiratory Tract Infections

Skin Diseases, Bacterial

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)

Bipolar Disorder (Phase 4)

Disease (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 1